Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 81
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
Mol Ther ; 29(10): 3059-3071, 2021 10 06.
Article in English | MEDLINE | ID: mdl-34111562

ABSTRACT

Parkinson's disease (PD) is characterized by Lewy bodies (composed predominantly of alpha-synuclein [aSyn]) and loss of pigmented midbrain dopaminergic neurons comprising the nigrostriatal pathway. Most PD patients show significant deficiency of gangliosides, including GM1, in the brain, and GM1 ganglioside appears to keep dopaminergic neurons functioning properly. Thus, supplementation of GM1 could potentially provide some rescuing effects. In this study, we demonstrate that intranasal infusion of GD3 and GM1 gangliosides reduces intracellular aSyn levels. GM1 also significantly enhances expression of tyrosine hydroxylase (TH) in the substantia nigra pars compacta of the A53T aSyn overexpressing mouse, following restored nuclear expression of nuclear receptor related 1 (Nurr1, also known as NR4A2), an essential transcription factor for differentiation, maturation, and maintenance of midbrain dopaminergic neurons. GM1 induces epigenetic activation of the TH gene, including augmentation of acetylated histones and recruitment of Nurr1 to the TH promoter region. Our data indicate that intranasal administration of gangliosides could reduce neurotoxic proteins and restore functional neurons via modulating chromatin status by nuclear gangliosides.


Subject(s)
G(M1) Ganglioside/administration & dosage , Gangliosides/administration & dosage , Parkinson Disease/drug therapy , Tyrosine 3-Monooxygenase/metabolism , alpha-Synuclein/metabolism , Administration, Intranasal , Animals , Cell Line , Disease Models, Animal , Down-Regulation , Epigenesis, Genetic/drug effects , G(M1) Ganglioside/pharmacology , Gangliosides/pharmacology , Gene Expression Regulation/drug effects , Humans , Male , Mice , Parkinson Disease/genetics , Parkinson Disease/metabolism , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Tyrosine 3-Monooxygenase/genetics
2.
Neuromolecular Med ; 23(3): 428-443, 2021 09.
Article in English | MEDLINE | ID: mdl-33432492

ABSTRACT

The 20% ethanol extract of Polygala tenuifolia, Angelica tenuissima, and Dimocarpus longan (WIN-1001X) was derived from a modified version of Korean traditional herbal formula 'Chungsimyeolda-tang' which has been used for the treatment of cerebrovascular disorders. The Parkinson's disease presents with impaired motor functions and loss of dopaminergic neurons. However, the treatment for Parkinson's disease is not established until now. This study aims to elucidate the therapeutic advantages of WIN-1001X on animal models of Parkinson's disease. WIN-1001X administration successfully relieved the Parkinsonism symptoms in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease mice tested by rota-rod and pole tests. The loss of tyrosine hydroxylase activities in substantia nigra and striatum was also attenuated by administration of WIN-1001X. In mice with sub-chronical MPTP injections, autophagy-related proteins, such as LC3, beclin-1, mTOR, and p62, were measured using the immunoblot assay. The results were favorable to induction of autophagy after the WIN-1001X administration. WIN-1001X treatment on 6-hydroxydopamine-injected rats also exhibited protective effects against striatal neuronal damage and loss of dopaminergic cells. Such protection is expected to be due to the positive regulation of autophagy by administration of WIN-1001X with confirmation both in vivo and in vitro. In addition, an active compound, onjisaponin B was isolated and identified from WIN-1001X. Onjisaponin B also showed significant autophagosome-inducing effect in human neuroblastoma cell line. Our study suggests that relief of Parkinsonism symptoms and rescue of tyrosine hydroxylase activity in dopaminergic neurons are affected by autophagy enhancing effect of WIN-1001X which the onjisaponin B is one of the major components of activity.


Subject(s)
Angelica/chemistry , Autophagy/drug effects , Neuroprotective Agents/therapeutic use , Parkinsonian Disorders/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Polygala/chemistry , Sapindaceae/chemistry , Animals , Apomorphine/pharmacology , Cell Line, Tumor , Corpus Striatum/enzymology , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/enzymology , Drug Evaluation, Preclinical , Humans , Male , Mice , Mice, Inbred C57BL , Molecular Structure , Neuroblastoma/pathology , Neuroprotective Agents/pharmacology , Oxidopamine/toxicity , Plant Extracts/pharmacology , Random Allocation , Rats , Rats, Sprague-Dawley , Rotarod Performance Test , Saponins/chemistry , Saponins/pharmacology , Saponins/therapeutic use , Substantia Nigra/enzymology , Triterpenes/chemistry , Triterpenes/pharmacology , Triterpenes/therapeutic use , Tyrosine 3-Monooxygenase/analysis
3.
Chin J Nat Med ; 16(7): 490-498, 2018 Jul.
Article in English | MEDLINE | ID: mdl-30080647

ABSTRACT

The traditionally used oriental herbal medicine Moutan Cortex Radicis [MCR; Paeonia Suffruticosa Andrews (Paeoniaceae)] exerts anti-inflammatory, anti-spasmodic, and analgesic effects. In the present study, we investigated the therapeutic effects of differently fractioned MCR extracts in a 6-hydroxydopamine (OHDA)-induced Parkinson's disease model and neuro-blastoma B65 cells. Ethanol-extracted MCR was fractionated by n-hexane, butanol, and distilled water. Adult Sprague-Dawley rats were treated first with 20 µg of 6-OHDA, followed by three MCR extract fractions (100 or 200 mg·kg-1) for 14 consecutive days. In the behavioral rotation experiment, the MCR extract-treated groups showed significantly decreased number of net turns compared with the 6-OHDA control group. The three fractions also significantly inhibited the reduction in tyrosine hydroxylase-positive cells in the substantia nigra pars compacta following 6-OHDA neurotoxicity. Western blotting analysis revealed significantly reduced tyrosine hydroxylase expression in the substantia nigra pars compacta in the 6-OHDA-treated group, which was significantly inhibited by the n-hexane or distilled water fractions of MCR. B65 cells were exposed to the extract fractions for 24 h prior to addition of 6-OHDA for 30 min; treatment with n-hexane or distilled water fractions of MCR reduced apoptotic cell death induced by 6-OHDA neurotoxicity and inhibited nitric oxide production and neuronal nitric oxide synthase expression. These results showed that n-hexane- and distilled water-fractioned MCR extracts inhibited 6-OHDA-induced neurotoxicity by suppressing nitric oxide production and neuronal nitric oxide synthase activity, suggesting that MCR extracts could serve as a novel candidate treatment for the patients with Parkinson's disease.


Subject(s)
Antiparkinson Agents/therapeutic use , Drugs, Chinese Herbal/chemistry , Oxidopamine/toxicity , Paeonia/chemistry , Parkinsonian Disorders/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antiparkinson Agents/pharmacology , Cell Death/drug effects , Cell Line , Disease Models, Animal , Neurons/pathology , Nitric Oxide/analysis , Nitric Oxide Synthase Type I/biosynthesis , Parkinsonian Disorders/chemically induced , Plant Extracts/pharmacology , Plants, Medicinal , Rats , Rats, Sprague-Dawley , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism
4.
BMC Complement Altern Med ; 18(1): 76, 2018 Feb 23.
Article in English | MEDLINE | ID: mdl-29475448

ABSTRACT

BACKGROUND: Methamphetamine (METH) is a psychostimulant with high abuse liability that affects the monoamine neurotransmitter systems, particularly the dopamine system. Currently there are no effective medications for the treatment of METH abuse to restore METH-induced dopaminergic dysfunction. The Jitai tablet (JTT), a commercial traditional Chinese medicinal preparation, has been shown to modulate the dopaminergic function both in heroin addicts and in morphine-dependent rats. The purpose of this study was to investigate, in a rodent model, whether JTT can protect against METH-induced neurotoxicity, and/or restore METH-damaged dopaminergic function. METHODS: Immunohistochemical staining and/or autoradiography staining were used to detect tyrosine hydroxylase (TH) expression in the substantia nigra, and to examine the levels of dopamine transporter (DAT), dopamine D2 receptor (D2R) and TH levels in the striatum. Using a stereotyped behavior rating scale, we evaluated the inhibitory effect of JTT on METH-induced behavioral sensitization. RESULTS: Repeated METH administration induced obvious stereotyped behavior and neurotoxicity on the dopaminergic system. Pre-treatment with JTT significantly attenuated METH-induced stereotyped responses, and interdicted METH-induced changes in the levels of DAT, D2R and TH expression. Treatment with JTT after METH administration restored DAT, D2R and TH expression to normal levels. CONCLUSIONS: Our results indicated that JTT protects against METH-induced neurotoxicity and restores the dopaminergic function, and thus might be a potential treatment for the dopaminergic deficits associated with METH abuse.


Subject(s)
Dopamine/metabolism , Drugs, Chinese Herbal/administration & dosage , Methamphetamine/toxicity , Neuroprotective Agents/administration & dosage , Neurotoxicity Syndromes/drug therapy , Animals , Behavior, Animal/drug effects , Humans , Male , Medicine, Chinese Traditional , Neurotoxicity Syndromes/genetics , Neurotoxicity Syndromes/metabolism , Neurotoxicity Syndromes/psychology , Rats , Rats, Wistar , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/metabolism , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Tablets/administration & dosage , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism
5.
Neurol Res ; 39(10): 918-925, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28738742

ABSTRACT

Recently, we demonstrated that inhibition of ERK1/2 activity by SL-327 treatment blocks seizure behavior in Krushinsky-Molodkina (KM) rats, which was mediated by altering of GABA and glutamate release mechanism in the hippocampus. Basal ganglia representing various subcortical cell groups play a significant role in the regulation of motor activity, including epileptiform seizures. OBJECTIVES:  To verify if nigrostriatal system could be also affected by SL-327 treatment we analyzed the expression of tyrosine hydroxylase, D1 and D2 dopamine receptors, NR2B subunit of NMDA receptor as well as vesicular glutamate transporter VGLUT2 and glutamic acid decarboxylases GAD65/67 in the striatum and substantia nigra of KM rats. METHODS: Animals were injected i.p. with SL-327 (50 mg/kg) 60 min before audio stimulation. After audiogenic stimulation the brains of control and SL 327 treated rats were removed for further immunohistochemical and biochemical analysis. RESULTS:  Obtained results demonstrated a decrease activity in synapsin I, and accumulation of VGLUT2 in the striatum after blockade of audiogenic seizure (AGS) by SL 327 that could lead to inhibition of glutamate release. While in the striatum GAD65/67 level was diminished, in the substantia nigra GAD65/67 was increased showing enhanced inhibitory output to the compact part of the substantia nigra. Analysis of dopaminergic system showed a significant reduction of tyrosine hydroxylase activity and expression in the substantia nigra, and decreased D1 and D2 receptor expression in the striatum. In summary, we propose that changes in the nigrostriatal system could be mediated by inhibitory effect of SL 327 on AGS expression.


Subject(s)
Corpus Striatum/enzymology , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3/antagonists & inhibitors , Seizures/enzymology , Substantia Nigra/enzymology , Acoustic Stimulation , Aminoacetonitrile/analogs & derivatives , Aminoacetonitrile/pharmacology , Animals , Auditory Perception/physiology , Corpus Striatum/drug effects , Disease Models, Animal , Female , Glutamic Acid/metabolism , Male , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Neurons/drug effects , Neurons/enzymology , Protein Kinase Inhibitors/pharmacology , Rats , Seizures/drug therapy , Seizures/etiology , Substantia Nigra/drug effects , Synapsins/metabolism , gamma-Aminobutyric Acid/metabolism
6.
J Chem Neuroanat ; 80: 1-10, 2017 03.
Article in English | MEDLINE | ID: mdl-27919828

ABSTRACT

Parkinson's disease is one of the most common neurodegenerative disease found in aged peoples. Plentiful studies are being conducted to find a suitable and effective cure for this disease giving special impetus on use of herbal plants. The study aimed at investigating the effect of ethanolic extract of Mucuna pruriens (Mp) on level of nitric oxide (NO) in paraquat (PQ) induced Parkinson's disease (PD) mouse model and its subsequent contribution to lipid peroxidation. Twenty four Swiss albino mice were divided into three groups; Control, PQ and PQ+Mp. PQ doses were given intraperitoneally, twice in a week and oral dose of ethanolic extract of Mp seed was given for 9 weeks. Nitrite content and lipid peroxidation was measured in all treated groups along with respective controls. RNA was isolated from the nigrostriatal tissue of control and the treated mice and was reverse transcribed into cDNA. PCR was performed to amplify iNOS mRNA and western blot analysis was performed to check its protein level. We had also perfused the mice in all treated group and performed Tyrosine hydroxylase (TH) and iNOS immunoreactivity in substantia nigra region of mice brain. PQ-treatment increased nitrite content, expression of iNOS and lipid peroxidation compared to respective controls. Mp treatment resulted in a significant attenuation of iNOS expression, nitrite content and lipid peroxidation demonstrating that it reduces nitric oxide in PQ-induced Parkinson's disease. Interestingly; we also observed that mRNA, protein expression and immunoreactivity of iNOS was significantly decreased after Mp treatment and TH immunoreactivity was significantly improved after the treatment of Mp. Our results demonstrated that Mp protects the dopaminergic neurons from the NO injury in substantia nigra.


Subject(s)
Mucuna/chemistry , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/biosynthesis , Parkinson Disease, Secondary/enzymology , Plant Extracts/pharmacology , Animals , Behavior, Animal/drug effects , Corpus Striatum/drug effects , Corpus Striatum/enzymology , Lipid Peroxidation/drug effects , Male , Mice , Mice, Inbred C57BL , Nitric Oxide/metabolism , Nitrites/metabolism , Paraquat , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/psychology , RNA/biosynthesis , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Tyrosine 3-Monooxygenase/metabolism
7.
J Tradit Chin Med ; 37(2): 244-51, 2017 04.
Article in English | MEDLINE | ID: mdl-29960635

ABSTRACT

OBJECTIVE: To investigate the regulatory mechanism of the c-Jun N-terminal protein kinase (JNK) signaling pathway in substantia nigra (SN) dopaminergic neurons inflammation and apoptosis, and the neuroprotective effect of Zishenpingchan granules in mice with Parkinson's disease (PD) induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). METHODS: PD model mice were established by intraperitoneally injecting MPTP. Sixty mice were divided into a model group, Traditional Chinese Medicine (TCM) group and control group. The mice of the TCM group were administered Zishenpingchan granules 7 days before PD induction. Seven days after PD induction, we examined locomotor activity, and performed the rotarod test and swimming test, to evaluate limb movement function. Furthermore, we used immunohistochemistry and western blotting to examine the expression of tyrosine hydroxylase (TH), cyclooxygenase-2 (Cox-2), caspase-3 and p-JNK. The terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) method was used to examine neuron apoptosis in the SN. RESULTS: Compared with the control group, the mean score of locomotor activity, rotarod test and swimming test was significantly lower in the model group (P < 0.05); the TH-positive neuron expression was significantly decreased in the SN pars compacta (SNpc); the protein expression levels of Cox-2, caspase-3 and p-JNK was obviously increased; and the number of TUNEL-positive neurons in the SN was increased (P < 0.01). Compared with the model group, the mean score of neurobehavioral tests in the TCM group was obviously higher, the loss of TH-positive neurons ignificantly decreased, the protein expression levels of Cox-2, caspase-3 and p-JNK obviously decreased, and the number of TUNEL- positive neurons in the SN clearly decreased (P < 0.01). CONCLUSION: The JNK pathway plays an important role in the regulation of inflammation and apoptosis in nigral cells in PD mice. TCM can suppress the over-activation of the JNK pathway in the SN, and alleviate the inflammatory response in nigral cells and dopaminergic neuron apoptosis in PD mice.


Subject(s)
Drugs, Chinese Herbal/administration & dosage , JNK Mitogen-Activated Protein Kinases/metabolism , Neuroprotective Agents/administration & dosage , Parkinson Disease/drug therapy , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects , Animals , Apoptosis/drug effects , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Disease Models, Animal , Dopamine/metabolism , Humans , JNK Mitogen-Activated Protein Kinases/genetics , Male , Mice , Mice, Inbred C57BL , Parkinson Disease/enzymology , Parkinson Disease/genetics , Parkinson Disease/metabolism , Signal Transduction/drug effects , Substantia Nigra/enzymology , Substantia Nigra/metabolism , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism
8.
Neurotox Res ; 30(3): 486-98, 2016 10.
Article in English | MEDLINE | ID: mdl-27417698

ABSTRACT

Neuroinflammation has been reported to be involved in the pathogenesis of Parkinson's disease (PD). Inhibition of microglia-mediated neuroinflammation might be a potential strategy for PD treatment. Biochanin A, is an O-methylated isoflavone, classified as a kind of phytoestrogens due to its chemical structure that is similar to mammalian estrogens. It has been found to possess antifibrotic, antiapoptotic, and antioxidant effects. In the present study, we investigated the neuroprotective effects of biochanin A on lipopolysaccharide (LPS)-induced dopaminergic neurons damage both in vivo and in vitro and the related molecular mechanisms. The results showed that biochanin A treatment for 21 days significantly attenuated the behavioral dysfunction of PD rats, prevented dopaminergic neurons damage, and inhibited activation of microglia in the LPS-induced PD rats. Furthermore, biochanin A decreased the levels of interleukin-1ß (IL-1ß), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in the serum, and inhibited the phosphorylation of ERK, JNK, p38 in the substantia nigra of PD rats. In vitro test, biochanin A also inhibited primary microglial activation and protected dopaminergic neurons, decreased the content of nitric oxide, IL-1ß, and TNF-α in supernatants, and inhibited the reactive oxygen species production. Taken together, these results suggest that biochanin A exerts protective effects on LPS-induced PD rats, and the mechanisms may be associated with the inhibition of inflammatory response and the MAPK signaling pathway.


Subject(s)
Dopaminergic Neurons/drug effects , Dopaminergic Neurons/immunology , Genistein/pharmacology , Microglia/drug effects , Microglia/immunology , Neuroprotective Agents/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antiparkinson Agents/pharmacology , Cells, Cultured , Disease Models, Animal , Dopaminergic Neurons/pathology , Drug Evaluation, Preclinical , Lipopolysaccharides , Male , Microglia/pathology , Motor Activity/drug effects , Motor Activity/physiology , Neuroimmunomodulation/drug effects , Neuroimmunomodulation/physiology , Phosphorylation/drug effects , Random Allocation , Rats, Sprague-Dawley , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Substantia Nigra/immunology , Substantia Nigra/pathology
9.
Zhen Ci Yan Jiu ; 40(4): 259-64, 2015 Aug.
Article in Chinese | MEDLINE | ID: mdl-26502537

ABSTRACT

OBJECTIVE: To explore the role of 26 S proteasome and nuclear factor kappa B (NFκB) in substantia nigra in the management of Parkinson's disease (PD) by acupuncture. METHODS: Forty-eight male SD rats were randomly divided into normal, sham operation, model and electroacupuncture (EA) groups (12 rats/group).. The PD model was established by 40-day consecutive subcutaneous injection of rotenone (1 mg/kg dissolved in dimethyl sulfoxide and normal saline) at the back shoulder. The rats in the sham operation group were treated by subcutaneous injection of dose of saline. "Fengfu" (GV 16) and "Taichong" (LR 3) acupoints were stimulated with EA at 2 Hz, 1 mA, 20 min of duration in each treatment, and daily for 28 consecutive days. The behavioral changes of rats in each group were measured and scored at 40th day and 68th day, respectively. Immunohistochemistry was used to determine the expression of tyrosine hydroxylase (TH) used to detect the expression of 26 S proteasome and NFκB and TH were measured by Western blot. RESULTS: In comparison with the normal and sham operation groups, the behavioral scores of rats in the model group were elevated, which were significantly decreased by EA intervention (P < 0.05). The expression of TH and 26 S proteasome decreased whereas the NFκB increased in the rats of model group (P < 0.05); and EA intervention reversed these changes (all P < 0.05). CONCLUSION: EA intervention can improve PD rats' behavioral changes, which is pobably related to its effects in reducing loss of TH-positive neurons, down-regulating NFκB protein expression, and up- regulating 26 S proteasome protein expression in the substantia nigra.


Subject(s)
Electroacupuncture , NF-kappa B/metabolism , Parkinson Disease/therapy , Proteasome Endopeptidase Complex/metabolism , Substantia Nigra/metabolism , Acupuncture Points , Animals , Humans , Male , NF-kappa B/genetics , Parkinson Disease/enzymology , Parkinson Disease/genetics , Parkinson Disease/metabolism , Proteasome Endopeptidase Complex/genetics , Rats , Rats, Sprague-Dawley , Substantia Nigra/enzymology
10.
Zhongguo Zhen Jiu ; 35(4): 355-60, 2015 Apr.
Article in Chinese | MEDLINE | ID: mdl-26054145

ABSTRACT

OBJECTIVE: To explore the effects and action mechanism of electroacupuncture (EA) on Parkinson's disease (PD). METHODS: Forty-eight healthy male SD rats were randomly divided into a normal group, a sham operation group, a model group and an EA group, 12 rats in each one. Rats in the model group and EA group were treated with subcutaneous injection of rotenone (1mg/kg, dissolved in dimethyl sulfoxide and 0. 9 % normal saline) on neck and back for 40 days to establish rat model. Rats in the sham operation group were treated with injection of identical dose of dimethyl sulfoxide and 0. 9 %o normal saline at identical location which did not contain rotenone. After model establishment, rats in the EA group were treated with EA at "Fengfu" (GV 16) and "Taichong" (LR 3) with continuous wave (2 Hz, 1 mA), which was given 20 min per time, once a day for consecutive 28 days. Rats in the remaining groups were treated with fixation and immobilization without any other intervention. The rats behavioristics changes were observed and scored; immunohisto-chemistry was adopted to test the expression of tyrosine hydroxylase (TH); fluorescence spectrometry was used to detect the activities of 20 S ß1, ß2, ß5; western blot method was applied to measure the expression of 20S proteasome and its a subunit. RESULTS: Compared with the normal group and sham operation group, there was significant change of behavioristics in the model group, and TH positive neuron counting was obviously reduced; after treatment, the behavioristics score in the EA group was lower than that in the model group (P<0. 05), and TH positive neuron counting was significantly increased (P<0. 05). Compared with the normal group and sham operation group, the activities of 20 S ß1, ß2, ß5 in model group were significantly reduced (all P<0. 01), and those in the EA group were higher than those in the model group (P<0. 01). Compared with the normal group and sham operation group, the expression of 20S proteasome and its a subunit was reduced in the model group, and that in the EA group was higher than that in the model group (P<0. 05). CONCLUSION: EA could improve the loss of dopaminergic neurons induced by rotenone to prevent and treat PD, which is likely to be related with protecting the activity and expression of proteasomes in substantia nigra.


Subject(s)
Electroacupuncture , Parkinson Disease/therapy , Proteasome Endopeptidase Complex/metabolism , Substantia Nigra/enzymology , Animals , Disease Models, Animal , Humans , Male , Parkinson Disease/enzymology , Rats , Rats, Sprague-Dawley
11.
Free Radic Res ; 49(8): 1004-14, 2015.
Article in English | MEDLINE | ID: mdl-25791066

ABSTRACT

Melatonin is known to reduce detrimental effects of free radicals by stimulating antioxidant enzymes; however, its role has not been studied in 6-hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Therefore, we aimed to elucidate the effects of melatonin on motor activity and oxidative stress parameters in 6-OHDA-induced rat model of PD. Three-month-old male Wistar rats were divided into 5 groups: vehicle (V), melatonin-treated (M), 6-OHDA-injected (6-OHDA), 6-OHDA-injected + melatonin-treated (6-OHDA-Mel), and melatonin-treated + 6-OHDA-injected (Mel-6-OHDA) group. Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group. Rats received a unilateral stereotaxic injection of 6-OHDA into the right medial forebrain bundle. The 6-OHDA-Mel group started receiving melatonin when experimental PD was created and the treatment was continued for 7 days. In the Mel-6-OHDA group, experimental PD was created on the 23rd day of melatonin treatment and continued for the remaining 7 days. Locomotor activity decreased in 6-OHDA group compared with that in vehicle group; however, melatonin treatment did not improve this impairment. 6-OHDA injection caused an obvious reduction in tyrosine-hydroxylase-positive dopaminergic neuron viability as determined by immunohistochemistry. Melatonin supplementation decreased dopaminergic neuron death in 6-OHDA-Mel and Mel-6-OHDA groups compared with that in 6-OHDA group. Biochemical analysis confirmed the beneficial effects of melatonin displaying higher superoxide dismutase, catalase, and glutathione peroxidase activities and lower lipid peroxidation in substantia nigra samples in comparison to non-treated 6-OHDA group. Starting melatonin treatment before creating experimental PD was more effective on observed changes.


Subject(s)
Free Radical Scavengers/pharmacology , Melatonin/pharmacology , Neuroprotective Agents/pharmacology , Parkinson Disease, Secondary/drug therapy , Animals , Catalase/metabolism , Drug Evaluation, Preclinical , Glutathione Peroxidase/metabolism , Lipid Peroxidation , Male , Medial Forebrain Bundle/pathology , Motor Activity , Oxidopamine , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/metabolism , Rats, Wistar , Substantia Nigra/enzymology , Superoxide Dismutase/metabolism , Tyrosine 3-Monooxygenase/metabolism
12.
Zhen Ci Yan Jiu ; 39(3): 185-91, 2014 Jun.
Article in Chinese | MEDLINE | ID: mdl-25069193

ABSTRACT

OBJECTIVE: To observe the effect of electroacupuncture (EA) on superoxide (SOD), glutathione peroxidase (GSH-Px) activity, contents of glutathione (GSH) and malondiadehyde (MDA), and expression of tyrosine hydroxylase (TH) and apoptosis of Dopaminergic (DA) neurons in Substantia Nigra of rats with Parkinson's disease (PD). METHODS: Adult male Wistar rats were randomly divided into normal (10 rats), model (11 rats), EA (11 rats) and medication (11 rats) groups. The PD model was established by i.h. of Rotenone (0.8 mg/kg) for 28 days. EA stimulation (2 Hz/80 Hz, 2 mA) was applied at "Baihui" (GV 20), "Sanyinjiao" (SP 6) and "Taichong" (LR 3) acupoints for 10 min, once per day for 14 times. For rats in the medication group, Madopar suspension fluid (1.67 mg/kg) was given by gavage for 14 days. Xanthine oxidase method and colorimetric ana- lysis method were used to examine the SOD, GSH-Px activity and contents of GSH and MDA in the Substantia Nigra tissue of the right brain, respectively. Immunohistochemical technique was used to detect the TH positive neurons and TUNEL method was used to examine the apoptosis of DA neurons of the Substantia Nigra in the left brain. RESULTS: Following the intervention, the decreased SOD and GSH-Px activity, GSH contents, and the increased MDA content of the Substantia Nigra in PD rats were obviously reversed by EA intervention (P < 0.05) but not by medication except MDA content (P > 0.05). In comparison with the model group, the decreased TH immunoactivity, and the increased numbers of apoptotic cells of DA neurons were apparently suppressed in both EA and medication groups (P < 0.05), but without significant differences between the EA and the medication groups (P > 0.05). In addition, HE stain showed that EA intervention could improve PD-induced impairment of Substantia Nigra neurons (mild swelling of neurons with large nucleus and deranged fibers). CONCLUSION: EA intervention can reduce pathological changes of Substantial Nigra in PD rats, which is probably associated with its effects in up-regulating the SOD and GSH-Px activity, GSH contents, and down-regulating MDA level, and reducing the apoptosis of DA neurons of the Substantia Nigra, suggesting an anti-oxidative stress effect of EA therapy.


Subject(s)
Electroacupuncture , Glutathione Peroxidase/metabolism , Glutathione/metabolism , Malondialdehyde/metabolism , Parkinson Disease/therapy , Substantia Nigra/metabolism , Animals , Apoptosis , Dopaminergic Neurons/cytology , Dopaminergic Neurons/enzymology , Dopaminergic Neurons/metabolism , Glutathione Peroxidase/genetics , Humans , Male , Oxidative Stress , Parkinson Disease/genetics , Parkinson Disease/metabolism , Parkinson Disease/physiopathology , Rats , Substantia Nigra/cytology , Substantia Nigra/enzymology , Superoxides/metabolism
13.
Int J Mol Med ; 33(4): 870-8, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24535622

ABSTRACT

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of nigral dopaminergic neurons and a reduction in striatal dopaminergic fibers, which result in tremors, rigidity, bradykinesia and gait disturbance. In addition to motor dysfunction, dementia is a widely recognized symptom of patients with PD. Berberine, an isoquinoline alkaloid isolated from Berberis vulgaris L., is known to exert anxiolytic, analgesic, anti-inflammatory, antipsychotic, antidepressant and anti-amnesic effects. In the present study, we investigated the effects of berberine on short-term memory in relation to dopamine depletion and hippocampal neurogenesis using a mouse model of PD, induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid (MPTP/P) treatment. Mice in the berberine-treated groups were orally administered berberine once a day for a total of 5 weeks. Our results revealed that the injection of MPTP/P induced dopaminergic neuronal death in the substantia nigra and fiber loss in the striatum. This resulted in impaired motor balance and coordination, as assessed by the beam walking test. We further demonstrated that MPTP/P-induced apoptosis in the hippocampus deteriorated short-term memory, as shown by the step-down avoidance task. By contrast, neurogenesis in the hippocampal dentate gyrus, which is a compensatory adaptive response to excessive apoptosis, was increased upon PD induction. However, treatment with berberine enhanced motor balance and coordination by preventing dopaminergic neuronal damage. Treatment with berberine also improved short-term memory by inhibiting apoptosis in the hippocampus. Berberine demonstrated maximal potency at 50 mg/kg. Based on these data, treatment with berberine may serve as a potential therapeutic strategy for the alleviation of memory impairment and motor dysfunction in patients with PD.


Subject(s)
Apoptosis , Berberine/therapeutic use , Dopaminergic Neurons/pathology , Hippocampus/pathology , Parkinson Disease/drug therapy , Parkinson Disease/pathology , Substantia Nigra/pathology , Animals , Apoptosis/drug effects , Berberine/pharmacology , Caspase 3/metabolism , DNA Fragmentation/drug effects , Dentate Gyrus/drug effects , Dentate Gyrus/enzymology , Dentate Gyrus/pathology , Dentate Gyrus/physiopathology , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Hippocampus/drug effects , Hippocampus/physiopathology , Male , Memory, Short-Term/drug effects , Mice , Motor Activity/drug effects , Neurogenesis/drug effects , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Parkinson Disease/physiopathology , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Substantia Nigra/physiopathology , Tyrosine 3-Monooxygenase/metabolism , bcl-2-Associated X Protein/metabolism
14.
Zhen Ci Yan Jiu ; 38(3): 198-201, 2013 Jun.
Article in Chinese | MEDLINE | ID: mdl-24006664

ABSTRACT

OBJECTIVE: To observe the influence of electroacupuncture (EA) therapy on the expression of tyrosine hydroxylase (TH) and cyclooxygenase-2 (COX-2) proteins of Substantia Nigra cells(SNc) in the rotenone-induced Parkinson's disease(PD) rats, so as to explore the mechanism of EA underlying improvement of PD. METHODS: Forty rats were randomly divided into normal, sham-operation (sham), model and EA groups (n = 10/group). The PD model was established by successive subcutaneous injection of rotenone (highly selective lesions of nigrostriatal dopaminergic neurons) for 28 days. EA (2 Hz, 1 mA) was applied to bilateral "Fengfu" (GV 16) and "Taichong" (LR 3) for 20 min, once daily for 14 days. The expression levels of TH and COX-2 proteins in the Substantia Nigra of midbrain were detected with Western blotting. RESULTS: Compared with the normal group, the expression level of TH protein in the model group was significantly decreased (P < 0.01), and that of COX-2 protein in the model group was significantly increased (P < 0.01). After the EA treatment, the expression level of TH in the EA group was obviously upregulated (P < 0.01), and that of COX-2 protein in the EA group was considerably down-regulated (P < 0.01). No significant differences were found between the normal and sham groups in the expression levels of TH and COX-2 proteins (P > 0.05). CONCLUSION: EA therapy can decrease inflammation mediator COX-2 protein expression and upregulate TH protein expression in the Substantia Nigra of midbrain in PD rats, which may contribute to its effect in relieving PD in clinic.


Subject(s)
Acupuncture Points , Cyclooxygenase 2/genetics , Gene Expression , Parkinson Disease/therapy , Substantia Nigra/enzymology , Tyrosine 3-Monooxygenase/genetics , Animals , Cyclooxygenase 2/metabolism , Electroacupuncture , Humans , Male , Parkinson Disease/enzymology , Parkinson Disease/genetics , Rats , Rats, Sprague-Dawley , Tyrosine 3-Monooxygenase/metabolism , Up-Regulation
15.
Zhongguo Zhen Jiu ; 33(4): 329-33, 2013 Apr.
Article in Chinese | MEDLINE | ID: mdl-23819239

ABSTRACT

OBJECTIVE: To explore the role of inflammatory reaction mediated by p38-mitogen activated protein kinase (p38-MAPK) signal path on prevention and treatment of Parkinson disease (PD) model rats by electroacupuncture (EA). METHODS: Thirty-two healthy male SD rats were randomly divided into a normal group, a sham operation group, a model group and an EA group, eight rats in each one. The PD model was established in the model group and EA group by subcutaneous injection of rotenone in skin-back area (2 mg/kg, dissolved in sunflower oil, 2 mg/mL in density), while the injection of sunflower oil emulsion without rotenone at the same point and quantity as the model group was applied in the sham operation group. The normal group was not given any intervention. The EA treatment (continuous wave, 2 Hz in frequency, 1 mA in intensity, 20 min) was applied at "Fengfu" (GV 16) and "Taichong" (LR 3) in the EA group, once a day for continuously 14 days. No treatment was given in the other groups. The expression of tyrosine hydroxylase (TH), phosphorylated p38-MAPK, cyclooxygenase-2 (COX-2) in the substantia nigra were detected with immunohistochemical method. RESULTS: There was typical PD ethology change in the model group. Compared with the normal group and sham operation group, the expression of TH positive neuron in the substantia nigra in the model group was significantly decreased, while the expression of phosphorylated p38-MAPK and COX-2 were significantly increased (all P < 0.01). Compared with the model group, the expression of TH positive neuron in the EA group was apparently increased, while the expression of phosphorylated p38-MAPK and COX-2 were significantly decreased (all P < 0.01). CONCLUSION: The EA therapy could obviously reduce the expression of inflammation mediator COX-2, inhibit the phosphorylation of p38-MAPK, reduce the damage of dopaminergic neurons in the rats with PD, and this effect may be related with the impact of p38-MAPK signal path


Subject(s)
Electroacupuncture , Parkinson Disease/therapy , Substantia Nigra/enzymology , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Humans , Male , Parkinson Disease/enzymology , Parkinson Disease/genetics , Phosphorylation , Rats , Rats, Sprague-Dawley , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism , p38 Mitogen-Activated Protein Kinases/genetics
16.
Neurochem Int ; 62(8): 1039-47, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23562769

ABSTRACT

Parkinson's disease (PD) is a neurodegenerative disease which causes rigidity, resting tremor and postural instability. Treatment for this disease is still under investigation. Mucuna pruriens (L.), is a traditional herbal medicine, used in India since 1500 B.C., as a neuroprotective agent. In this present study, we evaluated the therapeutic effects of aqueous extract of M. pruriens (Mp) seed in Parkinsonian mouse model developed by chronic exposure to paraquat (PQ). Results of our study revealed that the nigrostriatal portion of Parkinsonian mouse brain showed significantly increased levels of nitrite, malondialdehyde (MDA) and reduced levels of catalase compared to the control. In the Parkinsonian mice hanging time was decreased, whereas narrow beam walk time and foot printing errors were increased. Treatment with aqueous seed extract of Mp significantly increased the catalase activity and decreased the MDA and nitrite level, compared to untreated Parkinsonian mouse brain. Mp treatment also improved the behavioral abnormalities. It increased hanging time, whereas it decreased narrow beam walk time and foot printing error compared to untreated Parkinsonian mouse brain. Furthermore, we observed a significant reduction in tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra (SN) and striatum region of the brain, after treatment with PQ which was considerably restored by the use of Mp seed extract. Our result suggested that Mp seed extract treatment significantly reduced the PQ induced neurotoxicity as evident by decrease in oxidative damage, physiological abnormalities and immunohistochemical changes in the Parkinsonian mouse.


Subject(s)
Behavior, Animal/drug effects , Corpus Striatum/drug effects , Disease Models, Animal , Mucuna/chemistry , Oxidative Stress/drug effects , Paraquat/toxicity , Parkinsonian Disorders/chemically induced , Plant Extracts/pharmacology , Seeds/chemistry , Substantia Nigra/drug effects , Animals , Catalase/metabolism , Corpus Striatum/enzymology , Corpus Striatum/metabolism , Male , Malondialdehyde/metabolism , Mice , Mucuna/embryology , Substantia Nigra/enzymology , Substantia Nigra/metabolism
17.
Gene ; 515(2): 329-38, 2013 Feb 25.
Article in English | MEDLINE | ID: mdl-23235115

ABSTRACT

Acupuncture stimulations at GB34 and LR3 inhibit the reduction of tyrosine hydroxylase in the nigrostriatal dopaminergic neurons in the parkinsonism animal models. Especially, behavioral tests showed that acupuncture stimulations improved the motor dysfunction in a previous study by almost 87.7%. The thalamus is a crucial area for the motor circuit and has been identified as one of the most markedly damaged areas in Parkinson's disease (PD), so acupuncture stimulations might also have an effect on the thalamic damage. In this study, gene expression changes following acupuncture at the acupoints were investigated in the thalamus of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism model using a whole transcript array. It was confirmed that acupuncture at these acupoints could inhibit the decrease of tyrosine hydroxylase in the thalamic regions of the MPTP model, while acupuncture at the non-acupoints could not suppress this decrease by its level shown in the acupoints. GeneChip gene array analysis showed that 18 (5 annotated genes: Dnase1l2, Dusp4, Mafg, Ndph and Pgm5) of the probes down-regulated in MPTP, as compared to the control, were exclusively up-regulated by acupuncture at the acupoints, but not at the non-acupoints. In addition, 14 (3 annotated genes; Serinc2, Sp2 and Ucp2) of the probes up-regulated in MPTP, as compared to the control, were exclusively down-regulated by acupuncture at the acupoints, but not at the non-acupoints. The expression levels of the representative genes in the microarray were validated by real-time RT-PCR. These results suggest that the 32 probes (8 annotated genes) which are affected by MPTP and acupuncture may be responsible for exerting the inhibitory effect of acupuncture in the thalamus which can be damaged by MPTP intoxication.


Subject(s)
Acupuncture Therapy , Gene Expression , MPTP Poisoning/enzymology , Thalamus/enzymology , Animals , Disease Models, Animal , Dopaminergic Neurons/enzymology , Gene Expression Regulation, Enzymologic , MPTP Poisoning/pathology , MPTP Poisoning/therapy , Male , Mice , Mice, Inbred C57BL , Oligonucleotide Array Sequence Analysis , Signal Transduction/genetics , Substantia Nigra/enzymology , Substantia Nigra/pathology , Thalamus/pathology , Transcriptome , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism
18.
Folia Histochem Cytobiol ; 50(2): 228-38, 2012 Jul 04.
Article in English | MEDLINE | ID: mdl-22763967

ABSTRACT

Docosahexaenoic acid (DHA), a major polyunsaturated fatty acid (PUFA) in the phospholipid fraction of the brain, is essential for normal cellular function. Neurodegenerative disorders such as Parkinson's disease (PD) often exhibit significant declines in PUFAs. The aim of this study was to observe the effects of DHA supplementation in an experimental rat model of PD created with '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine' (MPTP). Adult male Wistar rats were divided into four groups: (1) Control; (2) DHA-treated; (3) MPTP-induced; and (4) MPTP-induced + DHA-treated. Motor activity was investigated using the 'vertical pole' and 'vertical wire' tests. The dopaminergic lesion was determined by immunohistochemical analysis for tyrosine hydroxylase (TH)-immunopositive cells in substantia nigra (SN). Immunoreactivities of Bcl-2, Akt and phosphorylated-Akt (p-Akt) in SN were evaluated by immunohistochemistry. MPTP-induced animals exhibited decreased locomotor activity, motor coordination and loss of equilibrium. Diminished Parkinsonism symptoms and decreased dopaminergic neuron death were detected in the MPTP-induced + DHA-treated group compared to the MPTP-induced group. Moderate decreases in Akt staining were found in the MPTP-induced and MPTP-induced + DHA-treated groups compared to controls. p-Akt immunoreactivity decreased dramatically in the MPTP-induced group compared to the control; however, it was increased in the MPTP-induced + DHA-treated group compared to the MPTP-induced group. The staining intensity for Bcl-2 decreased prominently in the MPTP-induced group compared to the control, while it was stronger in the MPTP-induced + DHA-treated group compared to the MPTP-induced group. In conclusion, DHA significantly protects dopaminergic neurons against cell death in an experimental PD model. Akt/p-Akt and Bcl-2 pathways are related to this protective effect of DHA in experimental PD.


Subject(s)
Docosahexaenoic Acids/therapeutic use , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , Parkinson Disease/prevention & control , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Animals , Disease Models, Animal , Docosahexaenoic Acids/pharmacology , Male , Motor Activity/drug effects , Neuroprotective Agents/pharmacology , Parkinson Disease/pathology , Parkinson Disease/physiopathology , Phosphorylation/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Rats, Wistar , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Substantia Nigra/pathology , Tyrosine 3-Monooxygenase/metabolism
19.
Neurotoxicology ; 33(3): 321-31, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22342763

ABSTRACT

Hypothalamic tuberoinfundibular dopamine (TIDA) neurons remain unaffected in Parkinson disease (PD) while there is significant degeneration of midbrain nigrostriatal dopamine (NSDA) neurons. A similar pattern of susceptibility is observed in acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse and rotenone rat models of degeneration. It is not known if the resistance of TIDA neurons is a constitutive or induced cell-autonomous phenotype for this unique subset of DA neurons. In the present study, treatment with a single injection of MPTP (20 mg/kg; s.c.) was employed to examine the response of TIDA versus NSDA neurons to acute injury. An acute single dose of MPTP caused an initial loss of DA from axon terminals of both TIDA and NSDA neurons, with recovery occurring solely in TIDA neurons by 16 h post-treatment. Initial loss of DA from axon terminals was dependent on a functional dopamine transporter (DAT) in NSDA neurons but DAT-independent in TIDA neurons. The active metabolite of MPTP, 1-methyl, 4-phenylpyradinium (MPP+), reached higher concentration and was eliminated slower in TIDA compared to NSDA neurons, which indicates that impaired toxicant bioactivation or distribution is an unlikely explanation for the observed resistance of TIDA neurons to MPTP exposure. Inhibition of protein synthesis prevented TIDA neuron recovery, suggesting that the ability to recover from injury was dependent on an induced, rather than a constitutive cellular mechanism. Further, there were no changes in total tyrosine hydroxylase (TH) expression following MPTP, indicating that up-regulation of the rate-limiting enzyme in DA synthesis does not account for TIDA neuronal recovery. Differential candidate gene expression analysis revealed a time-dependent increase in parkin and ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1) expression (mRNA and protein) in TIDA neurons during recovery from injury. Parkin expression was also found to increase with incremental doses of MPTP. The increase in parkin expression occurred specifically within TIDA neurons, suggesting that these neurons have an intrinsic ability to up-regulate parkin in response to MPTP-induced injury. These data suggest that TIDA neurons have a compensatory mechanism to deal with toxicant exposure and increased oxidative stress, and this unique TIDA neuron phenotype provides a platform for dissecting the mechanisms involved in the natural resistance of central DA neurons following toxic insult.


Subject(s)
Basal Ganglia/drug effects , Dopaminergic Neurons/drug effects , Hypothalamus/drug effects , MPTP Poisoning/etiology , Striatonigral Degeneration/chemically induced , Substantia Nigra/drug effects , Ubiquitin Thiolesterase/metabolism , Ubiquitin-Protein Ligases/metabolism , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/administration & dosage , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/metabolism , Animals , Basal Ganglia/enzymology , Basal Ganglia/pathology , Dopamine/metabolism , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopaminergic Neurons/enzymology , Dopaminergic Neurons/pathology , Hypothalamus/enzymology , Hypothalamus/pathology , Injections, Subcutaneous , MPTP Poisoning/enzymology , MPTP Poisoning/genetics , MPTP Poisoning/pathology , Male , Mice , Mice, Inbred C57BL , Phenotype , RNA, Messenger/metabolism , Recovery of Function , Striatonigral Degeneration/enzymology , Striatonigral Degeneration/genetics , Striatonigral Degeneration/pathology , Substantia Nigra/enzymology , Substantia Nigra/pathology , Time Factors , Tyrosine 3-Monooxygenase/metabolism , Ubiquitin Thiolesterase/genetics , Ubiquitin-Protein Ligases/genetics , Up-Regulation
20.
Int J Neurosci ; 121(4): 209-17, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21265705

ABSTRACT

AIM: This study was designed to investigate the anti-inflammatory effects of bee venom (BV) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease (PD). METHOD: MPTP was administered by intraperitoneal (IP) injection at 2-hr intervals over an 8-hr period. Mice were then subjected to BV subcutaneous injection and sacrificed on days 1 and 3 following the final MPTP injection. The loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) was assessed by tyrosine hydroxylase (TH) immunohistochemistry. Microglial activation was measured by immunohistochemistry for macrophage antigen complex-1 (MAC-1) and inducible nitric oxide synthase (iNOS). The staining intensities of MAC-1 and iNOS were quantified with respect to optical density. RESULT: In animals treated with MPTP, the survival percentages of TH+ cells in the SNpc were 32% on day 1 and 46% on day 3 compared with normal mice. In BV-treated mice, the survival percentages of TH+ cells improved to 70% on day 1 and 78% on day 3 compared with normal mice. BV treatment also resulted in reduced expression of the inflammation markers MAC-1 and iNOS in the SNpc. CONCLUSION: These data suggest that BV injection may have a neuroprotective effect that attenuates the activation of the microglial response, which has implications for the treatment of PD.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Bee Venoms/therapeutic use , Inflammation Mediators/antagonists & inhibitors , Neurons/pathology , Parkinsonian Disorders/drug therapy , Parkinsonian Disorders/pathology , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/antagonists & inhibitors , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Bee Venoms/administration & dosage , Cell Death/drug effects , Cell Death/physiology , Disease Models, Animal , Dopamine Antagonists/administration & dosage , Dopamine Antagonists/therapeutic use , Inflammation Mediators/adverse effects , Male , Mice , Mice, Inbred C57BL , Neurons/drug effects , Neurons/enzymology , Neuroprotective Agents/therapeutic use , Random Allocation , Substantia Nigra/drug effects , Substantia Nigra/enzymology , Substantia Nigra/pathology , Tyrosine 3-Monooxygenase/biosynthesis , Tyrosine 3-Monooxygenase/physiology
SELECTION OF CITATIONS
SEARCH DETAIL